Adamis Pharmaceuticals market cap is $68.8 m, and annual revenue was $15.09 m in FY 2018

Adamis Pharmaceuticals Gross profit (Q2, 2019)2.1 M

Adamis Pharmaceuticals Gross profit margin (Q2, 2019), %36.4%

Adamis Pharmaceuticals Net income (Q2, 2019)-7.7 M

Adamis Pharmaceuticals EBIT (Q2, 2019)-7.7 M

Adamis Pharmaceuticals Cash, 30-Jun-20194.1 M

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|

## Revenue | 6.5m | 13.1m | 15.1m | ||

## Cost of goods sold | 4.9m | 7.4m | 9.8m | ||

## Gross profit | 1.6m | 5.7m | 5.3m | ||

| 25% | 43% | 35% | ||

## R&D expense | 1.0m | 4.8m | 9.7m | 7.5m | 18.8m |

## General and administrative expense | 3.4m | 9.0m | 17.1m | 22.8m | 25.9m |

## Operating expense total | 4.4m | 13.9m | 26.8m | 30.3m | 44.7m |

## EBIT | (4.4m) | (13.9m) | (25.2m) | (24.8m) | (39.5m) |

| (389%) | (190%) | (262%) | ||

## Interest expense | 8.6m | 214.4k | 231.3k | 157.8k | |

## Interest income | 9.3k | 102.2k | 245.4k | ||

## Income tax expense | 4.6m | 339.4k | 369.3k | ||

## Net Income | (8.2m) | (13.6m) | (19.4m) | (25.5m) | (39.0m) |

USD | Q2, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.9m | 2.1m | 3.0m | 3.8m | 3.4m | 3.2m | 3.9m | 3.8m | 4.9m | 5.8m | ||

## Cost of goods sold | 1.3m | 1.8m | 1.7m | 1.9m | 2.1m | 2.1m | 2.4m | 2.3m | 3.6m | 3.7m | ||

## Gross profit | 582.1k | 254.5k | 1.4m | 1.9m | 1.3m | 1.1m | 1.5m | 1.5m | 1.3m | 2.1m | ||

| 30% | 12% | 45% | 51% | 38% | 35% | 39% | 40% | 26% | 36% | ||

## R&D expense | 1.3m | 3.4m | 3.4m | 1.5m | 1.5m | 1.2m | 1.2m | 2.2m | 4.8m | 3.9m | 2.2m | 2.8m |

## General and administrative expense | 2.3m | 2.6m | 4.6m | 5.3m | 5.6m | 5.7m | 5.7m | 6.5m | 6.4m | 6.5m | 8.0m | 7.0m |

## Operating expense total | 3.5m | 6.0m | 8.0m | 6.8m | 7.1m | 6.8m | 7.0m | 8.7m | 19.9m | 10.4m | 10.2m | 9.8m |

## Depreciation and amortization | 2.3m | |||||||||||

## EBIT | (3.5m) | (6.0m) | (7.4m) | (6.6m) | (5.7m) | (4.9m) | (5.8m) | (7.6m) | (9.7m) | (8.9m) | (8.9m) | (7.7m) |

| (385%) | (317%) | (188%) | (129%) | (171%) | (239%) | (247%) | (232%) | (182%) | (134%) | ||

## Interest expense | 72.4k | 70.2k | 67.5k | 59.4k | 52.6k | 50.7k | 51.4k | 30.7k | 24.0k | 23.0k | ||

## Interest income | 167.0 | 1.3k | 4.0k | 5.2k | 39.7k | 39.1k | 21.5k | 66.0k | 74.4k | 34.1k | ||

## Net Income | (3.6m) | (6.4m) | (5.7m) | (6.6m) | (5.8m) | (5.0m) | (6.8m) | (7.6m) | (9.7m) | (8.9m) | (8.9m) | (7.7m) |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|

## Cash | 5.4m | 4.1m | 4.1m | 17.3m | 19.3m |

## Accounts Receivable | 805.4k | 830.1k | 1.2m | ||

## Inventories | 14.5k | 71.0k | 942.1k | 1.8m | 3.3m |

## Current Assets | 4.2m | 21.5m | 25.8m | ||

## PP&E | 6.6m | 9.9m | |||

## Goodwill | 7.6m | 7.6m | 7.6m | ||

## Total Assets | 15.1m | 12.1m | 37.8m | 51.4m | 58.4m |

## Accounts Payable | 671.0k | 497.8k | 2.2m | 2.9m | 4.2m |

## Short-term debt | 383.3k | ||||

## Current Liabilities | 8.6m | 8.8m | 11.6m | ||

## Long-term debt | 2.6m | ||||

## Total Debt | 383.3k | 2.6m | |||

## Total Liabilities | 2.9m | 2.7m | 12.5m | 11.9m | 11.7m |

## Additional Paid-in Capital | 58.3m | 78.3m | 113.7m | 153.5m | 199.7m |

## Retained Earnings | (46.1m) | (69.0m) | (88.5m) | (114.0m) | (153.0m) |

## Total Equity | 9.3m | 25.3m | 39.5m | 46.7m | |

## Debt to Equity Ratio | 0.1 x | ||||

## Debt to Assets Ratio | 0.1 x | ||||

## Financial Leverage | 1.3 x | 1.5 x | 1.3 x | 1.2 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|

## Depreciation and Amortization | 990.3k | 2.5m | 3.1m | 3.1m | |

## Accounts Receivable | |||||

## Inventories | 14.5k | (165.0k) | 1.9k | (882.5k) | (5.0m) |

## Accounts Payable | (1.8m) | (289.2k) | (1.7m) | 587.2k | 846.1k |

## Cash From Operating Activities | 5.4m | 306.0k | |||

## Purchases of PP&E | (97.1k) | (121.1k) | (2.1m) | (3.5m) | |

## Cash From Investing Activities | (10.0m) | 260.7k | (2.1m) | (3.5m) | |

## Short-term Borrowings | (38.7k) | ||||

## Cash From Financing Activities | 22.2m | 10.6m | 21.9m | 30.5m | 37.1m |

## Interest Paid | 1.2m | 89.4k | 229.6k | 216.8k | 181.3k |

## Income Taxes Paid | 2.4k | 19.0k | 16.7k | 5.6k |

USD | Q1, 2015 | Q2, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Depreciation and Amortization | 495.1k | 247.6k | 966.6k | 1.8m | 782.6k | 1.6m | 2.3m | 770.9k | 1.5m | 2.3m | 791.9k | 1.5m | ||||

## Accounts Receivable | 744.7k | 595.6k | 1.2m | |||||||||||||

## Inventories | (282.1k) | (112.9k) | 27.9k | (7.9k) | (54.0k) | (514.7k) | (785.3k) | (1.4m) | (808.2k) | (175.2k) | ||||||

## Accounts Payable | 547.7k | 750.0k | 977.2k | (289.0k) | 408.8k | 1.0m | 316.7k | (2.1m) | 562.9k | (256.5k) | (400.3k) | (1.1m) | 1.2m | 603.1k | (66.3k) | 369.6k |

## Purchases of PP&E | (16.8k) | (16.8k) | (48.0k) | (615.5k) | (1.5m) | (201.1k) | (1.3m) | (3.2m) | (1.7m) | (2.2m) | ||||||

## Cash From Investing Activities | 365.0k | (64.2k) | (1.5m) | (201.1k) | (3.2m) | (1.7m) | ||||||||||

## Cash From Financing Activities | 10.6m | 5.0m | 7.1m | 21.2m | (115.3k) | 14.3m | 30.6m | (119.7k) | 37.3m | (142.0k) | ||||||

## Interest Paid | 175.5k | 39.7k | 130.9k | 182.8k | 50.4k | 108.8k | 156.1k | 24.4k | 47.0k | |||||||

## Income Taxes Paid | 46.1k | 2.4k | 2.4k | 912.0 | 13.6k | 13.6k | 8.7k | 8.7k | 9.6k |

USD | Y, 2019 |
---|---|

## Financial Leverage | 1.4 x |